NeOnc Technologies (NTHI) vs Nutriband (NTRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nutriband (NTRB) has outperformed NeOnc Technologies (NTHI) over the past year, losing 28.8% versus a loss of 79.1%. Nutriband is the larger company by market cap ($73.5 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | NTRB |
|---|---|---|
| Share price | $2.53 | $6.05 |
| Market cap | $72.88M | $73.54M |
| 1-day change | -6.64% | -10.44% |
| YTD return | -69.41% | +33.26% |
| 1-year return | -79.07% | -28.82% |
| 5-year return | — | -11.15% |
| EPS (TTM) | $-2.13 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $9.19 |
| 52-week low | $2.52 | $2.80 |
| Distance from 52-week high | -79.07% | -34.13% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +571.94% | +147.93% |
| Average volume | 195.17K | 62.42K |
| Shares outstanding | 28.81M | 12.16M |
| Employees | 5 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTRB has outperformed NTHI by 50.3 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Healthcare · Biotechnology · 5 employees
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Healthcare · Biotechnology
NTHI vs NTRB FAQ
Which is bigger, NeOnc Technologies or Nutriband?
Nutriband (NTRB) is larger, with a market capitalization of $73.54M compared with $72.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, NTHI or NTRB?
NTRB returned -28.82% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Nutriband in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.